NCT06144970 - Study to Determine the Safety and Tolerability of TG-C in Subjects with Back Pain Due to Degenerative Disc Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2027

Conditions

Degenerative Disc Disease

Interventions

BIOLOGICAL

TG-C High Dose

High Dose - 1 mL of the combined TG-C cells

BIOLOGICAL

TG-C Mid Dose

Middle Dose - A volume of 2 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected

BIOLOGICAL

TG-C Low Dose

Low Dose - A volume of 9 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected

BIOLOGICAL

Sham Control

Single subcutaneous injection of normal saline